Clinical Trial

Kamuvudine-9 (K9) in Diabetic Macular Edema

Study acronym: K9
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-03.
Trial Details
NCT Number NCT07458061
Lead Sponsor Dr. Bryan Strelow
Conditions Diabetic Macular Edema
Enrollment 10 participants
Start Date 2026-02
Primary Completion 2026-06 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-10